# A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

> **NCT05568797** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1045 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA vaccine
- **BIOLOGICAL:** FLU vaccine

## Key facts

- **NCT ID:** NCT05568797
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-14
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-07-17
- **Target enrollment:** 1045 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05568797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05568797, "A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05568797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*